{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:31:32Z","timestamp":1791268292373,"version":"4.1.0"},"reference-count":232,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T00:00:00Z","timestamp":1221523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T00:00:00Z","timestamp":1221523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1038\/mp.2008.96","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T08:10:32Z","timestamp":1221552632000},"page":"469-486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":220,"title":["Clearance mechanisms of Alzheimer's amyloid-\u03b2 peptide: implications for therapeutic design and diagnostic tests"],"prefix":"10.1038","volume":"14","author":[{"given":"K A","family":"Bates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Verdile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q-X","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Ames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C L","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R N","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,9,16]]},"reference":[{"key":"BFmp200896_CR1","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW . Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885\u2013890.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFmp200896_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","volume":"122","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW . Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1131\u20131135.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFmp200896_CR3","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1002\/j.1460-2075.1985.tb04000.x","volume":"4","author":"CL Masters","year":"1985","unstructured":"Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K . Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 1985; 4: 2757\u20132763.","journal-title":"EMBO J"},{"key":"BFmp200896_CR4","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1074\/jbc.271.8.4077","volume":"271","author":"YM Kuo","year":"1996","unstructured":"Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996; 271: 4077\u20134081.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0021-9258(18)48529-8","volume":"267","author":"D Burdick","year":"1992","unstructured":"Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A et al. Assembly and aggregation properties of synthetic Alzheimer's A4\/beta amyloid peptide analogs. J Biol Chem 1992; 267: 546\u2013554.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR6","doi-asserted-by":"crossref","first-page":"17741","DOI":"10.1016\/S0021-9258(17)32503-6","volume":"269","author":"C Haass","year":"1994","unstructured":"Haass C, Hung AY, Selkoe DJ, Teplow DB . Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem 1994; 269: 17741\u201317748.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.phrs.2003.12.028","volume":"50","author":"G Verdile","year":"2004","unstructured":"Verdile G, Fuller S, Atwood CS, Laws SM, Gandy SE, Martins RN . The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 2004; 50: 397\u2013409.","journal-title":"Pharmacol Res"},{"key":"BFmp200896_CR8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1471-4159.2004.02737.x","volume":"91","author":"O Wirths","year":"2004","unstructured":"Wirths O, Multhaup G, Bayer TA . A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide\u2014the first step of a fatal cascade. J Neurochem 2004; 91: 513\u2013520.","journal-title":"J Neurochem"},{"key":"BFmp200896_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"A Alzheimer","year":"1995","unstructured":"Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR . An English translation of Alzheimer's 1907 paper, \u2018Uber eine eigenartige Erkankung der Hirnrinde\u2019. Clin Anat 1995; 8: 429\u2013431.","journal-title":"Clin Anat"},{"key":"BFmp200896_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1126\/science.8424174","volume":"259","author":"XD Cai","year":"1993","unstructured":"Cai XD, Golde TE, Younkin SG . Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science 1993; 259: 514\u2013516.","journal-title":"Science"},{"key":"BFmp200896_CR11","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/360672a0","volume":"360","author":"M Citron","year":"1992","unstructured":"Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992; 360: 672\u2013674.","journal-title":"Nature"},{"key":"BFmp200896_CR12","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/hmg\/6.12.2087","volume":"6","author":"CB Eckman","year":"1997","unstructured":"Eckman CB, Mehta ND, Crook R, Perez-tur J, Prihar G, Pfeiffer E et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 1997; 6: 2087\u20132089.","journal-title":"Hum Mol Genet"},{"key":"BFmp200896_CR13","doi-asserted-by":"publisher","first-page":"32247","DOI":"10.1074\/jbc.272.51.32247","volume":"272","author":"MS Forman","year":"1997","unstructured":"Forman MS, Cook DG, Leight S, Doms RW, Lee VM . Differential effects of the Swedish mutant amyloid precursor protein on beta-amyloid accumulation and secretion in neurons and nonneuronal cells. J Biol Chem 1997; 272: 32247\u201332253.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704\u2013706.","journal-title":"Nature"},{"key":"BFmp200896_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1126\/science.1411576","volume":"258","author":"GD Schellenberg","year":"1992","unstructured":"Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258: 668\u2013671.","journal-title":"Science"},{"key":"BFmp200896_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754\u2013760.","journal-title":"Nature"},{"key":"BFmp200896_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ng1292-330","volume":"2","author":"P St George-Hyslop","year":"1992","unstructured":"St George-Hyslop P, Haines J, Rogaev E, Mortilla M, Vaula G, Pericak-Vance M et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet 1992; 2: 330\u2013334.","journal-title":"Nat Genet"},{"key":"BFmp200896_CR18","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.8191290","volume":"264","author":"N Suzuki","year":"1994","unstructured":"Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos Jr L, Eckman C et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994; 264: 1336\u20131340.","journal-title":"Science"},{"key":"BFmp200896_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/ng1292-335","volume":"2","author":"C Van Broeckhoven","year":"1992","unstructured":"Van Broeckhoven C, Backhovens H, Cruts M, De Winter G, Bruyland M, Cras P et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3. Nat Genet 1992; 2: 335\u2013339.","journal-title":"Nat Genet"},{"key":"BFmp200896_CR20","first-page":"443","volume":"35","author":"LR Weitkamp","year":"1983","unstructured":"Weitkamp LR, Nee L, Keats B, Polinsky RJ, Guttormsen S . Alzheimer disease: evidence for susceptibility loci on chromosomes 6 and 14. Am J Hum Genet 1983; 35: 443\u2013453.","journal-title":"Am J Hum Genet"},{"key":"BFmp200896_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1212\/WNL.46.3.707","volume":"46","author":"JC Morris","year":"1996","unstructured":"Morris JC, Storandt M, McKeel Jr DW, Rubin EH, Price JL, Grant EA et al. Cerebral amyloid deposition and diffuse plaques in \u2018normal\u2019 aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996; 46: 707\u2013719.","journal-title":"Neurology"},{"key":"BFmp200896_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/00005072-199904000-00008","volume":"58","author":"DG Davis","year":"1999","unstructured":"Davis DG, Schmitt FA, Wekstein DR, Markesbery WR . Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999; 58: 376\u2013388.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFmp200896_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S0197-4580(02)00050-7","volume":"23","author":"GM Bishop","year":"2002","unstructured":"Bishop GM, Robinson SR . The amyloid hypothesis: let sleeping dogmas lie? Neurobiol Aging 2002; 23: 1101\u20131105.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3233\/JAD-2001-3206","volume":"3","author":"J Fonte","year":"2001","unstructured":"Fonte J, Miklossy J, Atwood C, Martins R . The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-beta levels: resolubilization of amyloid-beta with transition metal ion chelators. J Alzheimers Dis 2001; 3: 209\u2013219.","journal-title":"J Alzheimers Dis"},{"key":"BFmp200896_CR25","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853\u2013862.","journal-title":"Am J Pathol"},{"key":"BFmp200896_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860\u2013866.","journal-title":"Ann Neurol"},{"key":"BFmp200896_CR27","doi-asserted-by":"publisher","first-page":"10365","DOI":"10.1523\/JNEUROSCI.0630-07.2007","volume":"27","author":"MT Fodero-Tavoletti","year":"2007","unstructured":"Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 2007; 27: 10365\u201310371.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/exnr.1999.7085","volume":"158","author":"J Wang","year":"1999","unstructured":"Wang J, Dickson DW, Trojanowski JQ, Lee VM . The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999; 158: 328\u2013337.","journal-title":"Exp Neurol"},{"key":"BFmp200896_CR29","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.nbd.2003.11.024","volume":"15","author":"E Hellstrom-Lindahl","year":"2004","unstructured":"Hellstrom-Lindahl E, Mousavi M, Ravid R, Nordberg A . Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer's patients. Neurobiol Dis 2004; 15: 351\u2013360.","journal-title":"Neurobiol Dis"},{"key":"BFmp200896_CR30","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1073\/pnas.0205689101","volume":"101","author":"R Li","year":"2004","unstructured":"Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 2004; 101: 3632\u20133637.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR31","doi-asserted-by":"publisher","first-page":"20631","DOI":"10.1074\/jbc.271.34.20631","volume":"271","author":"AE Roher","year":"1996","unstructured":"Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ et al. Morphology and toxicity of Abeta-(1\u201342) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996; 271: 20631\u201320635.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR32","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al. Diffusible, nonfibrillar ligands derived from Abeta1\u201342 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448\u20136453.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0006-8993(01)03058-X","volume":"924","author":"HW Wang","year":"2002","unstructured":"Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B et al. Soluble oligomers of beta amyloid (1\u201342) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002; 924: 133\u2013140.","journal-title":"Brain Res"},{"key":"BFmp200896_CR34","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.1523\/JNEUROSCI.19-20-08876.1999","volume":"19","author":"DM Hartley","year":"1999","unstructured":"Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM et al. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19: 8876\u20138884.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR35","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nature04533","volume":"440","author":"S Lesne","year":"2006","unstructured":"Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352\u2013357.","journal-title":"Nature"},{"key":"BFmp200896_CR36","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1523\/JNEUROSCI.4800-06.2007","volume":"27","author":"LM Billings","year":"2007","unstructured":"Billings LM, Green KN, McGaugh JL, LaFerla FM . Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci 2007; 27: 751\u2013761.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR37","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1021\/bi972029u","volume":"37","author":"MB Podlisny","year":"1998","unstructured":"Podlisny MB, Walsh DM, Amarante P, Ostaszewski BL, Stimson ER, Maggio JE et al. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 1998; 37: 3602\u20133611.","journal-title":"Biochemistry"},{"key":"BFmp200896_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nn1372","volume":"8","author":"JP Cleary","year":"2005","unstructured":"Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005; 8: 79\u201384.","journal-title":"Nat Neurosci"},{"key":"BFmp200896_CR39","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1523\/JNEUROSCI.5543-03.2004","volume":"24","author":"T Kawarabayashi","year":"2004","unstructured":"Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T et al. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2004; 24: 3801\u20133809.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306\u2013319.","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"BFmp200896_CR41","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1007\/s00259-007-0700-2","volume":"35","author":"A Nordberg","year":"2008","unstructured":"Nordberg A . Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging 2008; 35 (Suppl 1): S46\u2013S50.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BFmp200896_CR42","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456\u20131465.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR43","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1212\/01.wnl.0000260969.94695.56","volume":"68","author":"NM Kemppainen","year":"2007","unstructured":"Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603\u20131606.","journal-title":"Neurology"},{"key":"BFmp200896_CR44","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837\u20132844.","journal-title":"Brain"},{"key":"BFmp200896_CR45","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718\u20131725.","journal-title":"Neurology"},{"key":"BFmp200896_CR46","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.neurobiolaging.2005.03.006","volume":"26","author":"I Blasko","year":"2005","unstructured":"Blasko I, Kemmler G, Krampla W, Jungwirth S, Wichart I, Jellinger K et al. Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Neurobiol Aging 2005; 26: 1135\u20131143.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR47","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","volume":"61","author":"R Mayeux","year":"2003","unstructured":"Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003; 61: 1185\u20131190.","journal-title":"Neurology"},{"key":"BFmp200896_CR48","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A","volume":"46","author":"R Mayeux","year":"1999","unstructured":"Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C et al. Plasma amyloid beta-peptide 1\u201342 and incipient Alzheimer's disease. Ann Neurol 1999; 46: 412\u2013416.","journal-title":"Ann Neurol"},{"key":"BFmp200896_CR49","first-page":"914","volume":"13","author":"N Pomara","year":"2005","unstructured":"Pomara N, Willoughby LM, Sidtis JJ, Mehta PD . Selective reductions in plasma Abeta 1\u201342 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 2005; 13: 914\u2013917.","journal-title":"Am J Geriatr Psychiatry"},{"key":"BFmp200896_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/archneurol.2007.57","volume":"65","author":"J Sundelof","year":"2008","unstructured":"Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Arch Neurol 2008; 65: 256\u2013263.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR51","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/archneur.64.3.354","volume":"64","author":"NR Graff-Radford","year":"2007","unstructured":"Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ et al. Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64: 354\u2013362.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR52","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","volume":"5","author":"M van Oijen","year":"2006","unstructured":"van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM . Plasma Abeta(1\u201340) and Abeta(1\u201342) and the risk of dementia: a prospective case-cohort study. Lancet Neurol 2006; 5: 655\u2013660.","journal-title":"Lancet Neurol"},{"key":"BFmp200896_CR53","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ . CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652\u2013656.","journal-title":"Neurology"},{"key":"BFmp200896_CR54","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512\u2013519.","journal-title":"Ann Neurol"},{"key":"BFmp200896_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0304-3940(95)12059-D","volume":"199","author":"L Lannfelt","year":"1995","unstructured":"Lannfelt L, Basun H, Vigo-Pelfrey C, Wahlund LO, Winblad B, Lieberburg I et al. Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Neurosci Lett 1995; 199: 203\u2013206.","journal-title":"Neurosci Lett"},{"key":"BFmp200896_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228\u2013234.","journal-title":"Lancet Neurol"},{"key":"BFmp200896_CR57","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/archneur.55.7.937","volume":"55","author":"D Galasko","year":"1998","unstructured":"Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937\u2013945.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR58","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1212\/01.WNL.0000156914.16988.56","volume":"64","author":"SK Herukka","year":"2005","unstructured":"Herukka SK, Hallikainen M, Soininen H, Pirttila T . CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005; 64: 1294\u20131297.","journal-title":"Neurology"},{"key":"BFmp200896_CR59","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/ana.20639","volume":"58","author":"K Iqbal","year":"2005","unstructured":"Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M et al. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005; 58: 748\u2013757.","journal-title":"Ann Neurol"},{"key":"BFmp200896_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/15622970310029912","volume":"4","author":"N Andreasen","year":"2003","unstructured":"Andreasen N, Sjogren M, Blennow K . CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry 2003; 4: 147\u2013155.","journal-title":"World J Biol Psychiatry"},{"key":"BFmp200896_CR61","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/brain\/awl063","volume":"129","author":"M Bibl","year":"2006","unstructured":"Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K et al. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006; 129: 1177\u20131187.","journal-title":"Brain"},{"key":"BFmp200896_CR62","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00702-006-0537-z","volume":"113","author":"M Bibl","year":"2006","unstructured":"Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P et al. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J Neural Transm 2006; 113: 1771\u20131778.","journal-title":"J Neural Transm"},{"key":"BFmp200896_CR63","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000090363","volume":"2","author":"PD Mehta","year":"2005","unstructured":"Mehta PD, Pirttila T . Increased cerebrospinal fluid A beta38\/A beta42 ratio in Alzheimer disease. Neurodegener Dis 2005; 2: 242\u2013245.","journal-title":"Neurodegener Dis"},{"key":"BFmp200896_CR64","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000100926","volume":"23","author":"O Hansson","year":"2007","unstructured":"Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L et al. Prediction of Alzheimer's disease using the CSF Abeta42\/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2007; 23: 316\u2013320.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"BFmp200896_CR65","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/nm1438","volume":"12","author":"RJ Bateman","year":"2006","unstructured":"Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM . Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12: 856\u2013861.","journal-title":"Nat Med"},{"key":"BFmp200896_CR66","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nbt1142","volume":"23","author":"P Holliger","year":"2005","unstructured":"Holliger P, Hudson PJ . Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126\u20131136.","journal-title":"Nat Biotechnol"},{"key":"BFmp200896_CR67","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.molimm.2007.08.008","volume":"45","author":"RS Solorzano-Vargas","year":"2008","unstructured":"Solorzano-Vargas RS, Vasilevko V, Acero G, Ugen KE, Martinez R, Govezensky T et al. Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1\u201342. Mol Immunol 2008; 45: 881\u2013886.","journal-title":"Mol Immunol"},{"key":"BFmp200896_CR68","unstructured":"Wang YJ, Pollard A, Zhong JH, Dong XY, Wu XB, Zhou HD et al. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 2007; doi:10.1016\/jneurobiolaging.2007.06.013 (e-pub ahead of print)."},{"key":"BFmp200896_CR69","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/j.1471-4159.2007.04591.x","volume":"102","author":"JF Poduslo","year":"2007","unstructured":"Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007; 102: 420\u2013433.","journal-title":"J Neurochem"},{"key":"BFmp200896_CR70","doi-asserted-by":"publisher","first-page":"19232","DOI":"10.1073\/pnas.0703793104","volume":"104","author":"G Habicht","year":"2007","unstructured":"Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J et al. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing A protofibrils. Proc Natl Acad Sci USA 2007; 104: 19232\u201319237.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11 Suppl 1","key":"BFmp200896_CR71","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1161\/01.STR.0000143452.85382.d1","volume":"35","author":"R Deane","year":"2004","unstructured":"Deane R, Wu Z, Zlokovic BV . RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004; 35 (11 Suppl 1): 2628\u20132631.","journal-title":"Stroke"},{"key":"BFmp200896_CR72","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/S0169-409X(02)00160-6","volume":"54","author":"D Stern","year":"2002","unstructured":"Stern D, Yan SD, Yan SF, Schmidt AM . Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002; 54: 1615\u20131625.","journal-title":"Adv Drug Deliv Rev"},{"key":"BFmp200896_CR73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","volume":"114","author":"A Goldin","year":"2006","unstructured":"Goldin A, Beckman JA, Schmidt AM, Creager MA . Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597\u2013605.","journal-title":"Circulation"},{"key":"BFmp200896_CR74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/exnr.2001.7732","volume":"171","author":"LF Lue","year":"2001","unstructured":"Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29\u201345.","journal-title":"Exp Neurol"},{"key":"BFmp200896_CR75","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/382685a0","volume":"382","author":"SD Yan","year":"1996","unstructured":"Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685\u2013691.","journal-title":"Nature"},{"key":"BFmp200896_CR76","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nm890","volume":"9","author":"R Deane","year":"2003","unstructured":"Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907\u2013913.","journal-title":"Nat Med"},{"key":"BFmp200896_CR77","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1172\/JCI2029","volume":"102","author":"JB Mackic","year":"1998","unstructured":"Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS et al. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1\u201340. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 1998; 102: 734\u2013743.","journal-title":"J Clin Invest"},{"key":"BFmp200896_CR78","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1073\/pnas.94.10.5296","volume":"94","author":"S Du Yan","year":"1997","unstructured":"Du Yan S, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 5296\u20135301.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR79","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0092-8674(00)80801-6","volume":"97","author":"MA Hofmann","year":"1999","unstructured":"Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100\/calgranulin polypeptides. Cell 1999; 97: 889\u2013901.","journal-title":"Cell"},{"key":"BFmp200896_CR80","doi-asserted-by":"crossref","first-page":"18210","DOI":"10.1016\/S0021-9258(19)37174-1","volume":"267","author":"T Dyrks","year":"1992","unstructured":"Dyrks T, Dyrks E, Hartmann T, Masters C, Beyreuther K . Amyloidogenicity of beta A4 and beta A4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem 1992; 267: 18210\u201318217.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR81","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0925-4439(98)00014-3","volume":"1406","author":"YM Kuo","year":"1998","unstructured":"Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE . Irreversible dimerization\/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim Biophys Acta 1998; 1406: 291\u2013298.","journal-title":"Biochim Biophys Acta"},{"key":"BFmp200896_CR82","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1523\/JNEUROSCI.21-12-04183.2001","volume":"21","author":"D Pratico","year":"2001","unstructured":"Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM . Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 2001; 21: 4183\u20134187.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR83","doi-asserted-by":"publisher","first-page":"6421","DOI":"10.1074\/jbc.274.10.6421","volume":"274","author":"JT Rogers","year":"1999","unstructured":"Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H et al. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5\u2032-untranslated region sequences. J Biol Chem 1999; 274: 6421\u20136431.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR84","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1006\/exnr.2000.7393","volume":"163","author":"JG Sheng","year":"2000","unstructured":"Sheng JG, Zhu SG, Jones RA, Griffin WS, Mrak RE . Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol 2000; 163: 388\u2013391.","journal-title":"Exp Neurol"},{"key":"BFmp200896_CR85","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0304-3940(95)11976-4","volume":"198","author":"FP Bellinger","year":"1995","unstructured":"Bellinger FP, Madamba SG, Campbell IL, Siggins GR . Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci Lett 1995; 198: 95\u201398.","journal-title":"Neurosci Lett"},{"key":"BFmp200896_CR86","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1073\/pnas.94.4.1500","volume":"94","author":"CJ Heyser","year":"1997","unstructured":"Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH . Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA 1997; 94: 1500\u20131505.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR87","doi-asserted-by":"publisher","first-page":"15303","DOI":"10.1074\/jbc.271.26.15303","volume":"271","author":"SM Fine","year":"1996","unstructured":"Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, Dewhurst S et al. Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem 1996; 271: 15303\u201315306.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR88","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1532-5415.2006.00776.x","volume":"54","author":"D Geroldi","year":"2006","unstructured":"Geroldi D, Falcone C, Minoretti P, Emanuele E, Arra M, D'Angelo A . High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. J Am Geriatr Soc 2006; 54: 1149\u20131150.","journal-title":"J Am Geriatr Soc"},{"key":"BFmp200896_CR89","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1097\/01.hjh.0000177535.45785.64","volume":"23","author":"D Geroldi","year":"2005","unstructured":"Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005; 23: 1725\u20131729.","journal-title":"J Hypertens"},{"key":"BFmp200896_CR90","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1161\/01.ATV.0000160342.20342.00","volume":"25","author":"C Falcone","year":"2005","unstructured":"Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005; 25: 1032\u20131037.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFmp200896_CR91","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1001\/archneur.62.11.1734","volume":"62","author":"E Emanuele","year":"2005","unstructured":"Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 2005; 62: 1734\u20131736.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR92","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2174\/092986706777585013","volume":"13","author":"D Geroldi","year":"2006","unstructured":"Geroldi D, Falcone C, Emanuele E . Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971\u20131978.","journal-title":"Curr Med Chem"},{"key":"BFmp200896_CR93","doi-asserted-by":"publisher","first-page":"6460","DOI":"10.1073\/pnas.95.11.6460","volume":"95","author":"M Simons","year":"1998","unstructured":"Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K . Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95: 6460\u20136464.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR94","doi-asserted-by":"publisher","first-page":"16576","DOI":"10.1074\/jbc.273.26.16576","volume":"273","author":"DS Howland","year":"1998","unstructured":"Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD et al. Modulation of secreted beta-amyloid precursor protein and amyloid beta- peptide in brain by cholesterol. J Biol Chem 1998; 273: 16576\u201316582.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR95","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1073\/pnas.081620098","volume":"98","author":"K Fassbender","year":"2001","unstructured":"Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856\u20135861.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR96","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1074\/jbc.271.8.4436","volume":"271","author":"S Bodovitz","year":"1996","unstructured":"Bodovitz S, Klein WL . Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996; 271: 4436\u20134440.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR97","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/archneur.60.4.510","volume":"60","author":"GL Vega","year":"2003","unstructured":"Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjohann D, Moore C et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol 2003; 60: 510\u2013515.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR98","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0165-5728(97)00021-0","volume":"76","author":"DT Laskowitz","year":"1997","unstructured":"Laskowitz DT, Goel S, Bennett ER, Matthew WD . Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol 1997; 76: 70\u201374.","journal-title":"J Neuroimmunol"},{"key":"BFmp200896_CR99","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1212\/WNL.54.1.240","volume":"54","author":"RM Evans","year":"2000","unstructured":"Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000; 54: 240\u2013242.","journal-title":"Neurology"},{"key":"BFmp200896_CR100","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1006\/exnr.1994.1044","volume":"126","author":"DL Sparks","year":"1994","unstructured":"Sparks DL, Scheff SW, Hunsaker III JC, Liu H, Landers T, Gross DR . Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 1994; 126: 88\u201394.","journal-title":"Exp Neurol"},{"key":"BFmp200896_CR101","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1471-4159.2004.02521.x","volume":"90","author":"S Parvathy","year":"2004","unstructured":"Parvathy S, Ehrlich M, Pedrini S, Diaz N, Refolo L, Buxbaum JD et al. Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding. J Neurochem 2004; 90: 1005\u20131010.","journal-title":"J Neurochem"},{"key":"BFmp200896_CR102","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JAD-2005-8305","volume":"8","author":"K Balakrishnan","year":"2005","unstructured":"Balakrishnan K, Verdile G, Mehta PD, Beilby J, Nolan D, Galvao DA et al. Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J Alzheimers Dis 2005; 8: 269\u2013282.","journal-title":"J Alzheimers Dis"},{"key":"BFmp200896_CR103","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1006\/nbdi.2001.0422","volume":"8","author":"LM Refolo","year":"2001","unstructured":"Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8: 890\u2013899.","journal-title":"Neurobiol Dis"},{"key":"BFmp200896_CR104","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.nbd.2004.01.009","volume":"16","author":"AJ George","year":"2004","unstructured":"George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, Evin G et al. APP intracellular domain is increased and soluble Abeta is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis 2004; 16: 124\u2013132.","journal-title":"Neurobiol Dis"},{"key":"BFmp200896_CR105","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1212\/WNL.49.1.56","volume":"49","author":"DE Kang","year":"1997","unstructured":"Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 1997; 49: 56\u201361.","journal-title":"Neurology"},{"key":"BFmp200896_CR106","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B et al. Clearance of Alzheimer's amyloid-ss(1\u201340) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000; 106: 1489\u20131499.","journal-title":"J Clin Invest"},{"key":"BFmp200896_CR107","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.neuron.2004.07.017","volume":"43","author":"R Deane","year":"2004","unstructured":"Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K et al. LRP\/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43: 333\u2013344.","journal-title":"Neuron"},{"key":"BFmp200896_CR108","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.1073\/pnas.86.18.7260","volume":"86","author":"JR Duguid","year":"1989","unstructured":"Duguid JR, Bohmont CW, Liu NG, Tourtellotte WW . Changes in brain gene expression shared by scrapie and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 7260\u20137264.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR109","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1017\/S0317167100029796","volume":"16","author":"PC May","year":"1989","unstructured":"May PC, Johnson SA, Poirier J, Lampert-Etchells M, Finch CE . Altered gene expression in Alzheimer's disease brain tissue. Can J Neurol Sci 1989; 16: 473\u2013476.","journal-title":"Can J Neurol Sci"},{"key":"BFmp200896_CR110","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1006\/bbrc.1994.2580","volume":"204","author":"T Oda","year":"1994","unstructured":"Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE . Purification and characterization of brain clusterin. Biochem Biophys Res Commun 1994; 204: 1131\u20131136.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFmp200896_CR111","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/BF00296787","volume":"83","author":"NH Choi-Miura","year":"1992","unstructured":"Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe T et al. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol (Berl) 1992; 83: 260\u2013264.","journal-title":"Acta Neuropathol (Berl)"},{"key":"BFmp200896_CR112","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0006-8993(95)00482-6","volume":"685","author":"E Kida","year":"1995","unstructured":"Kida E, Choi-Miura NH, Wisniewski KE . Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. Brain Res 1995; 685: 211\u2013216.","journal-title":"Brain Res"},{"key":"BFmp200896_CR113","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0006-8993(92)90071-G","volume":"579","author":"PL McGeer","year":"1992","unstructured":"McGeer PL, Kawamata T, Walker DG . Distribution of clusterin in Alzheimer brain tissue. Brain Res 1992; 579: 337\u2013341.","journal-title":"Brain Res"},{"key":"BFmp200896_CR114","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/cne.903390307","volume":"339","author":"GM Pasinetti","year":"1994","unstructured":"Pasinetti GM, Johnson SA, Oda T, Rozovsky I, Finch CE . Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. J Comp Neurol 1994; 339: 387\u2013400.","journal-title":"J Comp Neurol"},{"issue":"Part 2","key":"BFmp200896_CR115","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1042\/bj3440375","volume":"344","author":"M Calero","year":"1999","unstructured":"Calero M, Tokuda T, Rostagno A, Kumar A, Zlokovic B, Frangione B et al. Functional and structural properties of lipid-associated apolipoprotein J (clusterin). Biochem J 1999; 344 (Part 2): 375\u2013383.","journal-title":"Biochem J"},{"issue":"Part 1","key":"BFmp200896_CR116","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1042\/bj2930027","volume":"293","author":"J Ghiso","year":"1993","unstructured":"Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T et al. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993; 293 (Part 1): 27\u201330.","journal-title":"Biochem J"},{"issue":"Part 2","key":"BFmp200896_CR117","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/bj3160671","volume":"316","author":"E Matsubara","year":"1996","unstructured":"Matsubara E, Soto C, Governale S, Frangione B, Ghiso J . Apolipoprotein J and Alzheimer's amyloid beta solubility. Biochem J 1996; 316 (Part 2): 671\u2013679.","journal-title":"Biochem J"},{"key":"BFmp200896_CR118","doi-asserted-by":"publisher","first-page":"10843","DOI":"10.1073\/pnas.162228299","volume":"99","author":"RB DeMattos","year":"2002","unstructured":"DeMattos RB, O'Dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2002; 99: 10843\u201310848.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR119","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1006\/exnr.1995.1080","volume":"136","author":"T Oda","year":"1995","unstructured":"Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1\u201342) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol 1995; 136: 22\u201331.","journal-title":"Exp Neurol"},{"key":"BFmp200896_CR120","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1046\/j.1471-4159.1996.67031324.x","volume":"67","author":"LN Boggs","year":"1996","unstructured":"Boggs LN, Fuson KS, Baez M, Churgay L, McClure D, Becker G et al. Clusterin (Apo J) protects against in vitro amyloid-beta (1\u201340) neurotoxicity. J Neurochem 1996; 67: 1324\u20131327.","journal-title":"J Neurochem"},{"key":"BFmp200896_CR121","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0896-6273(03)00850-X","volume":"41","author":"RB DeMattos","year":"2004","unstructured":"DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW et al. ApoE and clusterin cooperatively suppress abeta levels and deposition. Evidence that ApoE regulates extracellular abeta metabolism in vivo. Neuron 2004; 41: 193\u2013202.","journal-title":"Neuron"},{"key":"BFmp200896_CR122","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","volume":"27","author":"RD Bell","year":"2007","unstructured":"Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007; 27: 909\u2013918.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFmp200896_CR123","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1006\/bbrc.1994.2825","volume":"205","author":"BV Zlokovic","year":"1994","unstructured":"Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochem Biophys Res Commun 1994; 205: 1431\u20131437.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFmp200896_CR124","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1073\/pnas.93.9.4229","volume":"93","author":"BV Zlokovic","year":"1996","unstructured":"Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT et al. Glycoprotein 330\/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 1996; 93: 4229\u20134234.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR125","doi-asserted-by":"publisher","first-page":"32916","DOI":"10.1074\/jbc.271.51.32916","volume":"271","author":"AL Biere","year":"1996","unstructured":"Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ . Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996; 271: 32916\u201332922.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR126","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1046\/j.1471-4159.1998.70031182.x","volume":"70","author":"Y Du","year":"1998","unstructured":"Du Y, Bales KR, Dodel RC, Liu X, Glinn MA, Horn JW et al. Alpha2-macroglobulin attenuates beta-amyloid peptide 1\u201340 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J Neurochem 1998; 70: 1182\u20131188.","journal-title":"J Neurochem"},{"key":"BFmp200896_CR127","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1073\/pnas.95.6.3275","volume":"95","author":"SR Hughes","year":"1998","unstructured":"Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG et al. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA 1998; 95: 3275\u20133280.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR128","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1073\/pnas.92.6.2313","volume":"92","author":"S Eriksson","year":"1995","unstructured":"Eriksson S, Janciauskiene S, Lannfelt L . Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc Natl Acad Sci USA 1995; 92: 2313\u20132317.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR129","doi-asserted-by":"publisher","first-page":"26041","DOI":"10.1074\/jbc.270.44.26041","volume":"270","author":"S Janciauskiene","year":"1995","unstructured":"Janciauskiene S, Garcia de Frutos P, Carlemalm E, Dahlback B, Eriksson S . Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J Biol Chem 1995; 270: 26041\u201326044.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR130","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/(SICI)1097-4547(19961001)46:1<58::AID-JNR8>3.0.CO;2-E","volume":"46","author":"S Webster","year":"1996","unstructured":"Webster S, Rogers J . Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J Neurosci Res 1996; 46: 58\u201366.","journal-title":"J Neurosci Res"},{"key":"BFmp200896_CR131","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1006\/bbrc.1999.0552","volume":"257","author":"YM Kuo","year":"1999","unstructured":"Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS et al. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 1999; 257: 787\u2013791.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFmp200896_CR132","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1006\/bbrc.2000.2222","volume":"268","author":"YM Kuo","year":"2000","unstructured":"Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 2000; 268: 750\u2013756.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFmp200896_CR133","doi-asserted-by":"publisher","first-page":"15990","DOI":"10.1074\/jbc.274.23.15990","volume":"274","author":"B Bohrmann","year":"1999","unstructured":"Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Naslund J et al. Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. J Biol Chem 1999; 274: 15990\u201315995.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR134","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0009-8981(97)00207-6","volume":"270","author":"AR Koudinov","year":"1998","unstructured":"Koudinov AR, Berezov TT, Kumar A, Koudinova NV . Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 1998; 270: 75\u201384.","journal-title":"Clin Chim Acta"},{"key":"BFmp200896_CR135","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1194\/jlr.C500022-JLR200","volume":"47","author":"LM Wilson","year":"2006","unstructured":"Wilson LM, Pham CL, Jenkins AJ, Wade JD, Hill AF, Perugini MA et al. High density lipoproteins bind Abeta and apolipoprotein C-II amyloid fibrils. J Lipid Res 2006; 47: 755\u2013760.","journal-title":"J Lipid Res"},{"key":"BFmp200896_CR136","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00005072-199409000-00001","volume":"53","author":"BT Hyman","year":"1994","unstructured":"Hyman BT, Terry RD . Apolipoprotein E, A beta, and Alzheimer disease. J Neuropathol Exp Neurol 1994; 53: 427\u2013428.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFmp200896_CR137","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0065-3233(08)60642-7","volume":"45","author":"KH Weisgraber","year":"1994","unstructured":"Weisgraber KH . Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994; 45: 249\u2013302.","journal-title":"Adv Protein Chem"},{"key":"BFmp200896_CR138","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921\u2013923.","journal-title":"Science"},{"key":"BFmp200896_CR139","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0304-3940(97)13394-8","volume":"223","author":"K Taddei","year":"1997","unstructured":"Taddei K, Clarnette R, Gandy SE, Martins RN . Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett 1997; 223: 29\u201332.","journal-title":"Neurosci Lett"},{"key":"BFmp200896_CR140","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1046\/j.1471-4159.2003.01615.x","volume":"84","author":"SM Laws","year":"2003","unstructured":"Laws SM, Hone E, Gandy S, Martins RN . Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003; 84: 1215\u20131236.","journal-title":"J Neurochem"},{"key":"BFmp200896_CR141","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/sj.mp.4001097","volume":"7","author":"SM Laws","year":"2002","unstructured":"Laws SM, Hone E, Taddei K, Harper C, Dean B, McClean C et al. Variation at the APOE \u2212491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry 2002; 7: 886\u2013890.","journal-title":"Mol Psychiatry"},{"key":"BFmp200896_CR142","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 8098\u20138102.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR143","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1046\/j.1471-4159.1997.68020721.x","volume":"68","author":"DS Yang","year":"1997","unstructured":"Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN . Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 1997; 68: 721\u2013725.","journal-title":"J Neurochem"},{"key":"BFmp200896_CR144","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H","volume":"49","author":"MJ LaDu","year":"1997","unstructured":"LaDu MJ, Lukens JR, Reardon CA, Getz GS . Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. J Neurosci Res 1997; 49: 9\u201318.","journal-title":"J Neurosci Res"},{"key":"BFmp200896_CR145","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JAD-2005-7406","volume":"7","author":"E Hone","year":"2005","unstructured":"Hone E, Martins IJ, Jeoung M, Ji TH, Gandy SE, Martins RN . Alzheimer's disease amyloid-beta peptide modulates apolipoprotein E isoform specific receptor binding. J Alzheimers Dis 2005; 7: 303\u2013314.","journal-title":"J Alzheimers Dis"},{"key":"BFmp200896_CR146","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0006-8993(96)01324-8","volume":"749","author":"PL McGeer","year":"1997","unstructured":"McGeer PL, Walker DG, Pitas RE, Mahley RW, McGeer EG . Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates beta- amyloid protein activation of complement in vitro. Brain Res 1997; 749: 135\u2013138.","journal-title":"Brain Res"},{"key":"BFmp200896_CR147","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1523\/JNEUROSCI.18-01-00195.1998","volume":"18","author":"J Jordan","year":"1998","unstructured":"Jordan J, Galindo MF, Miller RJ, Reardon CA, Getz GS, LaDu MJ . Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci 1998; 18: 195\u2013204.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR148","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/archneur.55.7.1001","volume":"55","author":"MJ McNamara","year":"1998","unstructured":"McNamara MJ, Gomez-Isla T, Hyman BT . Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol 1998; 55: 1001\u20131004.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR149","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1073\/pnas.050004797","volume":"97","author":"DM Holtzman","year":"2000","unstructured":"Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 2892\u20132897.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR150","doi-asserted-by":"publisher","first-page":"10083","DOI":"10.1523\/JNEUROSCI.22-23-10083.2002","volume":"22","author":"RE Hartman","year":"2002","unstructured":"Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK et al. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J Neurosci 2002; 22: 10083\u201310087.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-2003-5101","volume":"5","author":"E Hone","year":"2003","unstructured":"Hone E, Martins IJ, Fonte J, Martins RN . Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 2003; 5: 1\u20138.","journal-title":"J Alzheimers Dis"},{"key":"BFmp200896_CR152","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/ng1197-263","volume":"17","author":"KR Bales","year":"1997","unstructured":"Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997; 17: 263\u2013264.","journal-title":"Nat Genet"},{"key":"BFmp200896_CR153","doi-asserted-by":"publisher","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","volume":"96","author":"KR Bales","year":"1999","unstructured":"Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 1999; 96: 15233\u201315238.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp200896_CR154","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.expneurol.2006.05.019","volume":"202","author":"K Ono","year":"2006","unstructured":"Ono K, Noguchi-Shinohara M, Samuraki M, Matsumoto Y, Yanase D, Iwasa K et al. Blood-borne factors inhibit Alzheimer's beta-amyloid fibril formation in vitro. Exp Neurol 2006; 202: 125\u2013132.","journal-title":"Exp Neurol"},{"key":"BFmp200896_CR155","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1515\/CCLM.2002.052","volume":"40","author":"R Scacchi","year":"2002","unstructured":"Scacchi R, Ruggeri M, Gambina G, Martini MC, Corbo RM . Alpha2-macroglobulin deletion polymorphism and plasma levels in late onset Alzheimer's disease. Clin Chem Lab Med 2002; 40: 333\u2013336.","journal-title":"Clin Chem Lab Med"},{"key":"BFmp200896_CR156","first-page":"256","volume":"7","author":"E Nishiyama","year":"1996","unstructured":"Nishiyama E, Iwamoto N, Kimura M, Arai H . Serum amyloid P component level in Alzheimer's disease. Dementia 1996; 7: 256\u2013259.","journal-title":"Dementia"},{"key":"BFmp200896_CR157","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/8726","volume":"22","author":"V Rudrasingham","year":"1999","unstructured":"Rudrasingham V, Wavrant-De Vrieze F, Lambert JC, Chakraverty S, Kehoe P, Crook R et al. Alpha-2 macroglobulin gene and Alzheimer disease. Nat Genet 1999; 22: 17\u201319; discussion 21\u201322.","journal-title":"Nat Genet"},{"key":"BFmp200896_CR158","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1212\/WNL.54.2.438","volume":"54","author":"RC Dodel","year":"2000","unstructured":"Dodel RC, Du Y, Bales KR, Gao F, Eastwood B, Glazier B et al. Alpha2 macroglobulin and the risk of Alzheimer's disease. Neurology 2000; 54: 438\u2013442.","journal-title":"Neurology"},{"key":"BFmp200896_CR159","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1212\/WNL.55.5.678","volume":"55","author":"MN Koster","year":"2000","unstructured":"Koster MN, Dermaut B, Cruts M, Houwing-Duistermaat JJ, Roks G, Tol J et al. The alpha2-macroglobulin gene in AD: a population-based study and meta-analysis. Neurology 2000; 55: 678\u2013684.","journal-title":"Neurology"},{"key":"BFmp200896_CR160","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/8729","volume":"22","author":"EA Rogaeva","year":"1999","unstructured":"Rogaeva EA, Premkumar S, Grubber J, Serneels L, Scott WK, Kawarai T et al. An alpha-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nat Genet 1999; 22: 19\u201322.","journal-title":"Nat Genet"},{"key":"BFmp200896_CR161","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/8724","volume":"22","author":"DJ Dow","year":"1999","unstructured":"Dow DJ, Lindsey N, Cairns NJ, Brayne C, Robinson D, Huppert FA et al. Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK. Nat Genet 1999; 22: 16\u201317; author reply 21\u201322.","journal-title":"Nat Genet"},{"key":"BFmp200896_CR162","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/1243","volume":"19","author":"D Blacker","year":"1998","unstructured":"Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19: 357\u2013360.","journal-title":"Nat Genet"},{"key":"BFmp200896_CR163","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000017035","volume":"9","author":"M Nybo","year":"1998","unstructured":"Nybo M, Olsen H, Jeune B, Andersen-Ranberg K, Holm Nielsen E, Svehag SE . Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dement Geriatr Cogn Disord 1998; 9: 126\u2013129.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"BFmp200896_CR164","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0304-3940(99)00631-X","volume":"273","author":"M Kimura","year":"1999","unstructured":"Kimura M, Asada T, Uno M, Machida N, Kasuya K, Taniguchi Y et al. Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci Lett 1999; 273: 137\u2013139.","journal-title":"Neurosci Lett"},{"key":"BFmp200896_CR165","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/sj.mp.4001083","volume":"7","author":"SM Laws","year":"2002","unstructured":"Laws SM, Clarnette RM, Taddei K, Martins G, Paton A, Hallmayer J et al. APOE-epsilon4 and APOE \u2212491A polymorphisms in individuals with subjective memory loss. Mol Psychiatry 2002; 7: 768\u2013775.","journal-title":"Mol Psychiatry"},{"key":"BFmp200896_CR166","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ana.10414","volume":"53","author":"ST DeKosky","year":"2003","unstructured":"DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment. Ann Neurol 2003; 53: 81\u201390.","journal-title":"Ann Neurol"},{"key":"BFmp200896_CR167","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0197-4580(00)00246-3","volume":"22","author":"R Scacchi","year":"2001","unstructured":"Scacchi R, Ruggeri M, Gambina G, Martini MC, Ferrari G, Corbo RM . Plasma alpha1-antichymotrypsin in Alzheimer's disease; relationships with APOE genotypes. Neurobiol Aging 2001; 22: 413\u2013416.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR168","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0022-510X(97)00221-9","volume":"154","author":"A Chauhan","year":"1998","unstructured":"Chauhan A, Pirttila T, Chauhan VP, Mehta P, Wisniewski HM . Aggregation of amyloid beta-protein as function of age and apolipoprotein E in normal and Alzheimer's serum. J Neurol Sci 1998; 154: 159\u2013163.","journal-title":"J Neurol Sci"},{"key":"BFmp200896_CR169","doi-asserted-by":"publisher","first-page":"45897","DOI":"10.1074\/jbc.M407668200","volume":"279","author":"J Ghiso","year":"2004","unstructured":"Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S et al. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 2004; 279: 45897\u201345908.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR170","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1537-1891(02)00198-2","volume":"38","author":"JB Mackic","year":"2002","unstructured":"Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol 2002; 38: 303\u2013313.","journal-title":"Vascul Pharmacol"},{"key":"BFmp200896_CR171","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1046\/j.1471-4159.1998.70010210.x","volume":"70","author":"JB Mackic","year":"1998","unstructured":"Mackic JB, Weiss MH, Miao W, Kirkman E, Ghiso J, Calero M et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 1998; 70: 210\u2013215.","journal-title":"J Neurochem"},{"key":"BFmp200896_CR172","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO . Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448\u2013452.","journal-title":"Nat Med"},{"key":"BFmp200896_CR173","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46\u201354.","journal-title":"Neurology"},{"key":"BFmp200896_CR174","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916\u2013919.","journal-title":"Nat Med"},{"key":"BFmp200896_CR175","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0169-409X(02)00158-8","volume":"54","author":"DM Holtzman","year":"2002","unstructured":"Holtzman DM, Bales KR, Paul SM, DeMattos RB . Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv Drug Deliv Rev 2002; 54: 1603\u20131613.","journal-title":"Adv Drug Deliv Rev"},{"key":"BFmp200896_CR176","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0002-9440(10)63296-8","volume":"165","author":"CA Lemere","year":"2004","unstructured":"Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004; 165: 283\u2013297.","journal-title":"Am J Pathol"},{"key":"BFmp200896_CR177","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1523\/JNEUROSCI.23-01-00029.2003","volume":"23","author":"Y Matsuoka","year":"2003","unstructured":"Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003; 23: 29\u201333.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR178","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1523\/JNEUROSCI.20-08-02926.2000","volume":"20","author":"E Carro","year":"2000","unstructured":"Carro E, Nunez A, Busiguina S, Torres-Aleman I . Circulating insulin-like growth factor I mediates effects of exercise on the brain. J Neurosci 2000; 20: 2926\u20132933.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR179","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1385\/MN:27:2:153","volume":"27","author":"E Carro","year":"2003","unstructured":"Carro E, Trejo JL, Nunez A, Torres-Aleman I . Brain repair and neuroprotection by serum insulin-like growth factor I. Mol Neurobiol 2003; 27: 153\u2013162.","journal-title":"Mol Neurobiol"},{"key":"BFmp200896_CR180","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/00002512-200016010-00003","volume":"16","author":"E Arvat","year":"2000","unstructured":"Arvat E, Broglio F, Ghigo E . Insulin-Like growth factor I: implications in aging. Drugs Aging 2000; 16: 29\u201340.","journal-title":"Drugs Aging"},{"key":"BFmp200896_CR181","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1006\/nbdi.2000.0311","volume":"7","author":"S Busiguina","year":"2000","unstructured":"Busiguina S, Fernandez AM, Barrios V, Clark R, Tolbert DL, Berciano J et al. Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol Dis 2000; 7: 657\u2013665.","journal-title":"Neurobiol Dis"},{"key":"BFmp200896_CR182","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/nm1202-793","volume":"8","author":"E Carro","year":"2002","unstructured":"Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I . Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002; 8: 1390\u20131397.","journal-title":"Nat Med"},{"key":"BFmp200896_CR183","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.neurobiolaging.2005.09.039","volume":"27","author":"E Carro","year":"2006","unstructured":"Carro E, Trejo JL, Spuch C, Bohl D, Heard JM, Torres-Aleman I . Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol Aging 2006; 27: 1618\u20131631.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR184","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.neurobiolaging.2005.06.015","volume":"27","author":"E Carro","year":"2006","unstructured":"Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F et al. Therapeutic actions of insulin-like growth factor I on APP\/PS2 mice with severe brain amyloidosis. Neurobiol Aging 2006; 27: 1250\u20131257.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR185","doi-asserted-by":"publisher","first-page":"32730","DOI":"10.1074\/jbc.273.49.32730","volume":"273","author":"WQ Qiu","year":"1998","unstructured":"Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273: 32730\u201332738.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR186","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1523\/JNEUROSCI.20-05-01657.2000","volume":"20","author":"K Vekrellis","year":"2000","unstructured":"Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V et al. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000; 20: 1657\u20131665.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR187","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1007527721160","volume":"25","author":"A Perez","year":"2000","unstructured":"Perez A, Morelli L, Cresto JC, Castano EM . Degradation of soluble amyloid beta-peptides 1\u201340, 1\u201342, and the Dutch variant 1\u201340Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 2000; 25: 247\u2013255.","journal-title":"Neurochem Res"},{"key":"BFmp200896_CR188","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0002-9440(10)63822-9","volume":"162","author":"DG Cook","year":"2003","unstructured":"Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162: 313\u2013319.","journal-title":"Am J Pathol"},{"key":"BFmp200896_CR189","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1212\/01.wnl.0000216274.58185.09","volume":"66","author":"JJ Kulstad","year":"2006","unstructured":"Kulstad JJ, Green PS, Cook DG, Watson GS, Reger MA, Baker LD et al. Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 2006; 66: 1506\u20131510.","journal-title":"Neurology"},{"key":"BFmp200896_CR190","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","volume":"53","author":"A Ott","year":"1999","unstructured":"Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM . Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 53: 1937\u20131942.","journal-title":"Neurology"},{"key":"BFmp200896_CR191","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/archneur.61.5.661","volume":"61","author":"Z Arvanitakis","year":"2004","unstructured":"Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA . Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661\u2013666.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR192","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/humu.20016","volume":"23","author":"N Ertekin-Taner","year":"2004","unstructured":"Ertekin-Taner N, Allen M, Fadale D, Scanlin L, Younkin L, Petersen RC et al. Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat 2004; 23: 334\u2013342.","journal-title":"Hum Mutat"},{"key":"BFmp200896_CR193","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/JAD-2002-4504","volume":"4","author":"X Ling","year":"2002","unstructured":"Ling X, Martins RN, Racchi M, Craft S, Helmerhorst E . Amyloid beta antagonizes insulin promoted secretion of the amyloid beta protein precursor. J Alzheimers Dis 2002; 4: 369\u2013374.","journal-title":"J Alzheimers Dis"},{"key":"BFmp200896_CR194","doi-asserted-by":"publisher","first-page":"RC221","DOI":"10.1523\/JNEUROSCI.22-10-j0001.2002","volume":"22","author":"L Xie","year":"2002","unstructured":"Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R . Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002; 22: RC221.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR195","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1096\/fj.03-0978fje","volume":"18","author":"L Ho","year":"2004","unstructured":"Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18: 902\u2013904.","journal-title":"FASEB J"},{"key":"BFmp200896_CR196","doi-asserted-by":"publisher","first-page":"11120","DOI":"10.1523\/JNEUROSCI.2860-04.2004","volume":"24","author":"L Zhao","year":"2004","unstructured":"Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 2004; 24: 11120\u201311126.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR197","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0896-6273(03)00787-6","volume":"40","author":"MA Leissring","year":"2003","unstructured":"Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003; 40: 1087\u20131093.","journal-title":"Neuron"},{"key":"BFmp200896_CR198","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1523\/JNEUROSCI.23-06-01992.2003","volume":"23","author":"RA Marr","year":"2003","unstructured":"Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003; 23: 1992\u20131996.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR199","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0304-3940(03)00030-2","volume":"339","author":"J Apelt","year":"2003","unstructured":"Apelt J, Ach K, Schliebs R . Aging-related down-regulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci Lett 2003; 339: 183\u2013186.","journal-title":"Neurosci Lett"},{"key":"BFmp200896_CR200","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cell.2005.01.015","volume":"120","author":"O Lazarov","year":"2005","unstructured":"Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005; 120: 701\u2013713.","journal-title":"Cell"},{"key":"BFmp200896_CR201","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1523\/JNEUROSCI.0496-05.2005","volume":"25","author":"PA Adlard","year":"2005","unstructured":"Adlard PA, Perreau VM, Pop V, Cotman CW . Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 2005; 25: 4217\u20134221.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR202","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/aje\/kwi092","volume":"161","author":"LJ Podewils","year":"2005","unstructured":"Podewils LJ, Guallar E, Kuller LH, Fried LP, Lopez OL, Carlson M et al. Physical activity, APOE genotype, and dementia risk: Findings from the Cardiovascular Health Cognition Study. Am J Epidemiol 2005; 161: 639\u2013651.","journal-title":"Am J Epidemiol"},{"key":"BFmp200896_CR203","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1474-4422(05)70198-8","volume":"4","author":"S Rovio","year":"2005","unstructured":"Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 2005; 4: 705\u2013711.","journal-title":"Lancet Neurol"},{"key":"BFmp200896_CR204","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1042\/BST0331101","volume":"33","author":"EA Eckman","year":"2005","unstructured":"Eckman EA, Eckman CB . Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005; 33: 1101\u20131105.","journal-title":"Biochem Soc Trans"},{"key":"BFmp200896_CR205","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s004010050412","volume":"91","author":"O Kosunen","year":"1996","unstructured":"Kosunen O, Soininen H, Paljarvi L, Heinonen O, Talasniemi S, Riekkinen Sr PJ . Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol (Berl) 1996; 91: 185\u2013193.","journal-title":"Acta Neuropathol (Berl)"},{"key":"BFmp200896_CR206","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1161\/01.STR.0000014421.15948.67","volume":"33","author":"JC de la Torre","year":"2002","unstructured":"de la Torre JC . Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33: 1152\u20131162.","journal-title":"Stroke"},{"key":"BFmp200896_CR207","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1523\/JNEUROSCI.21-08-02561.2001","volume":"21","author":"L Gasparini","year":"2001","unstructured":"Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 2001; 21: 2561\u20132570.","journal-title":"J Neurosci"},{"key":"BFmp200896_CR208","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1212\/01.WNL.0000065916.25128.25","volume":"60","author":"GS Watson","year":"2003","unstructured":"Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D et al. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003; 60: 1899\u20131903.","journal-title":"Neurology"},{"key":"BFmp200896_CR209","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1385\/ENDO:29:2:257","volume":"29","author":"AM Barron","year":"2006","unstructured":"Barron AM, Verdile G, Martins RN . The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms. Endocrine 2006; 29: 257\u2013269.","journal-title":"Endocrine"},{"key":"BFmp200896_CR210","doi-asserted-by":"publisher","first-page":"25785","DOI":"10.1074\/jbc.274.36.25785","volume":"274","author":"UK Misra","year":"1999","unstructured":"Misra UK, Gawdi G, Gonzalez-Gronow M, Pizzo SV . Coordinate regulation of the alpha(2)-macroglobulin signaling receptor and the low density lipoprotein receptor-related protein\/alpha(2)-macroglobulin receptor by insulin. J Biol Chem 1999; 274: 25785\u201325791.","journal-title":"J Biol Chem"},{"key":"BFmp200896_CR211","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0306-4530(02)00087-2","volume":"28","author":"S Craft","year":"2003","unstructured":"Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003; 28: 809\u2013822.","journal-title":"Psychoneuroendocrinology"},{"key":"BFmp200896_CR212","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/archpsyc.56.12.1135","volume":"56","author":"S Craft","year":"1999","unstructured":"Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 1999; 56: 1135\u20131140.","journal-title":"Arch Gen Psychiatry"},{"key":"BFmp200896_CR213","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1749-6632.2000.tb06371.x","volume":"903","author":"S Craft","year":"2000","unstructured":"Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann NY Acad Sci 2000; 903: 222\u2013228.","journal-title":"Ann NY Acad Sci"},{"key":"BFmp200896_CR214","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1037\/0735-7044.107.6.926","volume":"107","author":"S Craft","year":"1993","unstructured":"Craft S, Dagogo-Jack SE, Wiethop BV, Murphy C, Nevins RT, Fleischman S et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 1993; 107: 926\u2013940.","journal-title":"Behav Neurosci"},{"key":"BFmp200896_CR215","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0197-4580(95)02002-0","volume":"17","author":"S Craft","year":"1996","unstructured":"Craft S, Newcomer J, Kanne S, Dagogo-Jack S, Cryer P, Sheline Y et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 1996; 17: 123\u2013130.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR216","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2005.08.017","volume":"245","author":"GS Watson","year":"2006","unstructured":"Watson GS, Craft S . Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. J Neurol Sci 2006; 245: 21\u201333.","journal-title":"J Neurol Sci"},{"issue":"Suppl 1","key":"BFmp200896_CR217","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neurobiolaging.2005.08.021","volume":"26","author":"S Craft","year":"2005","unstructured":"Craft S . Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005; 26 (Suppl 1): 65\u201369.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR218","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/archneur.60.7.958","volume":"60","author":"H Fukumoto","year":"2003","unstructured":"Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC . Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 2003; 60: 958\u2013964.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR219","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM . Plasma and cerebrospinal fluid levels of amyloid beta proteins 1\u201340 and 1\u201342 in Alzheimer disease. Arch Neurol 2000; 57: 100\u2013105.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR220","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1212\/WNL.48.3.741","volume":"48","author":"T Kosaka","year":"1997","unstructured":"Kosaka T, Imagawa M, Seki K, Arai H, Sasaki H, Tsuji S et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 1997; 48: 741\u2013745.","journal-title":"Neurology"},{"key":"BFmp200896_CR221","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0022-510X(96)00143-8","volume":"141","author":"A Tamaoka","year":"1996","unstructured":"Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci 1996; 141: 65\u201368.","journal-title":"J Neurol Sci"},{"key":"BFmp200896_CR222","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864\u2013870.","journal-title":"Nat Med"},{"key":"BFmp200896_CR223","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","volume":"60","author":"CW Ritchie","year":"2003","unstructured":"Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685\u20131691.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR224","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3109\/13506120009146438","volume":"7","author":"H Vanderstichele","year":"2000","unstructured":"Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N et al. Standardization of measurement of beta-amyloid(1\u201342) in cerebrospinal fluid and plasma. Amyloid 2000; 7: 245\u2013258.","journal-title":"Amyloid"},{"key":"BFmp200896_CR225","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0197-4580(98)00012-8","volume":"19","author":"L Lannfelt","year":"1998","unstructured":"Lannfelt L . Biochemical diagnostic markers to detect early Alzheimer's disease. Neurobiol Aging 1998; 19: 165\u2013167.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR226","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1212\/01.wnl.0000171397.32851.bc","volume":"65","author":"M Moonis","year":"2005","unstructured":"Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 2005; 65: 323\u2013325.","journal-title":"Neurology"},{"key":"BFmp200896_CR227","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neulet.2005.03.051","volume":"383","author":"JP Jia","year":"2005","unstructured":"Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF . Cerebrospinal fluid tau, Abeta1\u201342 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett 2005; 383: 12\u201316.","journal-title":"Neurosci Lett"},{"key":"BFmp200896_CR228","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.neurobiolaging.2005.06.005","volume":"27","author":"B Ibach","year":"2006","unstructured":"Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 2006; 27: 1202\u20131211.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR229","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0197-4580(03)00086-1","volume":"25","author":"P Lewczuk","year":"2004","unstructured":"Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42\/Abeta40 ratio and total tau. Neurobiol Aging 2004; 25: 273\u2013281.","journal-title":"Neurobiol Aging"},{"key":"BFmp200896_CR230","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/archneur.58.3.373","volume":"58","author":"N Andreasen","year":"2001","unstructured":"Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001; 58: 373\u2013379.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR231","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B et al. Cerebrospinal fluid beta-amyloid(1\u201342) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673\u2013680.","journal-title":"Arch Neurol"},{"key":"BFmp200896_CR232","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.neurobiolaging.2006.05.006","volume":"28","author":"FH Bouwman","year":"2007","unstructured":"Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007; 28: 1070\u20131074.","journal-title":"Neurobiol Aging"}],"updated-by":[{"DOI":"10.1038\/mp.2008.123","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2009,11,18]],"date-time":"2009-11-18T00:00:00Z","timestamp":1258502400000}}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/mp200896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp200896","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp200896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:31:12Z","timestamp":1648780272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp200896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,16]]},"references-count":232,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["BFmp200896"],"URL":"https:\/\/doi.org\/10.1038\/mp.2008.96","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/mp.2008.123","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,16]]},"assertion":[{"value":"14 January 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2008","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2008","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2008","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}